These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32992737)

  • 41. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma.
    Cui C; Xu C; Yang W; Chi Z; Sheng X; Si L; Xie Y; Yu J; Wang S; Yu R; Guo J; Kong Y
    NPJ Genom Med; 2021 Feb; 6(1):7. PubMed ID: 33542239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer.
    Kang YB; Cai Y
    World J Gastroenterol; 2021 Aug; 27(32):5362-5375. PubMed ID: 34539138
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunological Agents Used in Cancer Treatment.
    Simsek M; Tekin SB; Bilici M
    Eurasian J Med; 2019 Feb; 51(1):90-94. PubMed ID: 30911265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer.
    Aghamajidi A; Maleki Vareki S
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.
    Maccalli C; Giannarelli D; Chiarucci C; Cutaia O; Giacobini G; Hendrickx W; Amato G; Annesi D; Bedognetti D; Altomonte M; Danielli R; Calabrò L; Di Giacomo AM; Marincola FM; Parmiani G; Maio M
    Oncoimmunology; 2017; 6(7):e1323618. PubMed ID: 28811958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma.
    Limeta A; Ji B; Levin M; Gatto F; Nielsen J
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
    Weber R; Fleming V; Hu X; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():1310. PubMed ID: 29942309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 59. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
    Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
    J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.